CSL gets grant for method of reducing GVHD risk in hct patients with a1at
Discover how CSL Ltd's patented method using alpha-1 antitrypsin (A1AT) can reduce the risk of graft versus host disease in hematopoietic cell transplantation patients. Published as US11857610B2, this groundbreaking approach offers hope for improved outcomes.
Discover how CSL Ltd's patented method using alpha-1 antitrypsin (A1AT) can reduce the risk of graft versus host disease in hematopoietic cell transplantation patients. Published as US11857610B2, this groundbreaking approach offers hope for improved outcomes.
What's Your Reaction?
